CHMP has adopted a positive opinion for Ivozall®
30 septembre 2019
ORPHELIA at the annual SIOP Congress
16 octobre 2019

Dr. Caroline Lemarchand appointed Chief Pharmaceutical Development Officer

ORPHELIA announces the appointment of Dr. Caroline Lemarchand as Chief Pharmaceutical Development Officer

Paris and Lyon, October 15th 2019 – ORPHELIA Pharma, a French biopharmaceutical company dedicated to the development and marketing of paediatric drugs in the fields of oncology and neurology, announces the appointment of Dr. Caroline Lemarchand as Chief Pharmaceutical Development Officer, effective September 16, 2019.

Caroline Lemarchand, PharmD, PhD, will bring to ORPHELIA Pharma her expertise in pharmaceutical development, acquired during a 20-year career in pharma and biotech companies. Caroline was successively working at Onxeo (formerly Bioalliance Pharma) as preclinical and pharmaceutical development Director before joining Stallergenes Greer as pharmaceutical development Director.

Caroline Lemarchand contributed to the development, registration and marketing of several drugs (innovative technologies, new chemical entities, biotherapy), especially in the field of oncology, both in Europe and in the United States. She authored numerous peer-reviewed scientific publications and patents.

« We are particularly pleased to welcome Caroline at ORPHELIA Pharma » comments Hugues Bienaymé, Founder and General Manager at ORPHELIA Pharma. « Her deep knowledge of pharmaceutical development and impressive track-record will be a significant asset for a company like ORPHELIA Pharma, which focuses on life-threatening paediatric conditions. Caroline will be instrumental in managing our collaborative partnerships to assemble a portfolio of essential drugs for children ».

 « I am excited to be joining ORPHELIA Pharma at this important inflection point with already 2 products approved and several collaborative projects running », says Caroline Lemarchand. « The company is in a privileged position to build a portfolio of drugs for the paediatric community, both in neurology and oncology. Since there are many collaborations already in place, I look forward to leading these partnerships and setting up some new projects ».

About ORPHELIA Pharma

ORPHELIA Pharma is a biopharmaceutical company based in Paris and Lyon that develops and markets drugs for the treatment of rare and serious paediatric diseases. Our mission is to provide patients with essential hospital products in the fields of epilepsy and oncology with formulations adapted to the paediatric population. Our first product, Kigabeq®, obtained its Marketing Authorization in October 2018 and has been launched in Europe. Our second product, Ivozall®, received a positive opinion from the CHMP in September 2019 recommending the issuance of a European marketing authorization. ORPHELIA Pharma also conducts research projects through academic and industrial collaborations. The main investors are initiative OCTALFA and Pierre Fabre Medicament.